FDA Cardio-Renal Cmte.
Executive Summary
NDAs for Merrell Dow's antihypertensive Atenupres (lofexidime), and Ives' antihypertensive/anti-anginal/anti-arrhythmic Sectral (acebutolol) will be discussed at cmte.'s Dec. 10-11 meeting. Agenda also includes Sterling's petition for use of aspirin in myocardial infarction prevention and Mead Johnson's Questran (cholestyreamine) for use in coronary artery disease